Table 2 Secondary endpoints: corneal thickness, maximal and minimal simulated K-readings and visual acuity in the placebo and treatment (CXL) group at the end of the trial
Placebo group | CXL group | ||
|---|---|---|---|
Corneal thickness (μm) at the end of follow-up | 467.3 +/−24 | 449.2 +/−72 | p = 0.96 |
Kmin (dpt) at the end of follow-up | 46.1 +/−4.7 | 43.5 +/−1.7 | p = 0.59 |
Kmax (dpt) at the end of follow-up | 51.2 +/−6.9 | 46.9 +/−2.1 | p = 0.59 |
Visual acuity (logMAR) at the end of follow-up | 0.23 +/−0.27 | 0.22 +/−0.14 | p = 0.61 |